Cingulate Inc
NASDAQ:CING

Watchlist Manager
Cingulate Inc Logo
Cingulate Inc
NASDAQ:CING
Watchlist
Price: 4.18 USD 5.29% Market Closed
Market Cap: 28.3m USD

Operating Margin
Cingulate Inc

0%
Current
0%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-20.6m
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Cingulate Inc
NASDAQ:CING
28.3m USD N/A
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
498.9B USD
27%
CH
Roche Holding AG
SIX:ROG
262B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
212.6B GBP
24%
CH
Novartis AG
SIX:NOVN
210.7B CHF
33%
US
Merck & Co Inc
NYSE:MRK
260.5B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
143.3B USD
29%
No Stocks Found

Cingulate Inc
Glance View

Market Cap
28.3m USD
Industry
Pharmaceuticals

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing and commercialization of pharmaceutical products that utilize precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improves the lives of patients suffering from a multitude of commonly diagnosed conditions. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form. Its CTx-1301 and CTx-1302 that are being developed for the treatment of ADHD, in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).

CING Intrinsic Value
4.75 USD
Undervaluation 12%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-20.6m
/
Revenue
0
What is the Operating Margin of Cingulate Inc?

Based on Cingulate Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top